Clinical Trials List
2018-02-01 - 2025-09-30
Phase III
Terminated3
ICD-10C50.911
Malignant neoplasm of unspecified site of right female breast
ICD-10C50.912
Malignant neoplasm of unspecified site of left female breast
ICD-10C50.919
Malignant neoplasm of unspecified site of unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.9
Malignant neoplasm of female breast, unspecified
-
Trial Applicant
GEORGE CLINICAL ASIA PACIFIC LIMITED
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 賴亦貞 Division of Radiology
- Ta-Chung Chao Division of Hematology & Oncology
- 林燕淑 Division of General Surgery
- Chun-Yu Liu Division of Hematology & Oncology
- 邱仁輝 Division of General Surgery
- Yi-Fang Tsai Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 褚乃銘 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 林季宏 Division of Hematology & Oncology
- 張端瑩 Division of Hematology & Oncology
- Wei-Wu Chen Division of Hematology & Oncology
- MING-YANG WANG Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
18 participants
-
Global
180 participants
